产品资料
  首页 >>> 产品目录 >>> 细胞因子 >>> 细胞**

重组人IFN-λ1/IL-29

产品名称: 重组人IFN-λ1/IL-29
产品型号: PP100137-5μg
产品展商: PERFEMIKER
产品价格: 600.00 元
会员价格: 0.00 元
产品文档: 无相关文档
我要买:
产品已经成功添加到购物车
你添加了1件产品 查看购物车

简单介绍

名称:重组人IFN-λ1/IL-29 货号:PP100137 规格:5μg


重组人IFN-λ1/IL-29  的详细介绍

名称:重组人IFN-λ1/IL-29

Synonyms:Cytokine Zcyto21

Species:9

Accession:Q8IU54

GeneID:282618

Source:Escherichia coli.

Molecular Weight:Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.

Quantity:5µg/20µg/1000µg

AA Sequence:GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T

Purity:> 97 % by SDS-PAGE and HPLC analyses.

Biological Activity:Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of > 2.0 × 105 IU/mg.

Physical Appearance:Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

Endotoxin:Less than 1 EU/μg of rHuIFN-λ1/IL-29 as determined by LAL method.

Reconstitution:We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Stability & Storage:Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reference:1. Miller EK, Hernandez JZ, Wimmenauer V, et al. 2012. Am J Respir Crit Care Med, 185: 508-16.
2. Li Y, Xie J, Xu X, et al. 2012. Protein Cell, 
3. Jordan WJ, Eskdale J, Srinivas S, et al. 2007. Genes Immun, 8: 254-61.
4. Pekarek V, Srinivas S, Eskdale J, et al. 2007. Genes Immun, 8: 177-80.
5. Megjugorac NJ, Gallagher GE, Gallagher G. 2010. Blood, 115: 4185-90.

Background:IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13 % a.a. sequence identity) and the type I IFN family (15-19 % a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN-λR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.